COSTI, Maria Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 33.379
EU - Europa 18.995
AS - Asia 14.310
SA - Sud America 2.086
AF - Africa 247
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 28
Totale 69.083
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.975
GB - Regno Unito 5.451
CN - Cina 5.147
IT - Italia 4.596
SG - Singapore 4.454
DE - Germania 2.565
SE - Svezia 1.854
BR - Brasile 1.714
HK - Hong Kong 1.693
RU - Federazione Russa 858
VN - Vietnam 816
FR - Francia 782
UA - Ucraina 642
FI - Finlandia 504
KR - Corea 492
TR - Turchia 427
PL - Polonia 394
IN - India 284
BG - Bulgaria 272
ID - Indonesia 265
CA - Canada 254
NL - Olanda 175
BE - Belgio 163
JP - Giappone 162
AR - Argentina 151
IE - Irlanda 136
ES - Italia 119
LT - Lituania 109
ZA - Sudafrica 105
MX - Messico 99
BD - Bangladesh 93
CH - Svizzera 85
IQ - Iraq 64
EC - Ecuador 58
IR - Iran 58
AT - Austria 56
MY - Malesia 52
PK - Pakistan 44
CZ - Repubblica Ceca 43
AE - Emirati Arabi Uniti 37
PY - Paraguay 36
CL - Cile 35
CO - Colombia 31
MA - Marocco 31
RO - Romania 29
UZ - Uzbekistan 29
PT - Portogallo 28
AU - Australia 26
EG - Egitto 25
VE - Venezuela 25
KE - Kenya 24
EU - Europa 21
JO - Giordania 20
SA - Arabia Saudita 20
KZ - Kazakistan 19
LU - Lussemburgo 19
TW - Taiwan 18
DK - Danimarca 16
PE - Perù 16
TN - Tunisia 16
AZ - Azerbaigian 14
PH - Filippine 14
UY - Uruguay 14
DZ - Algeria 13
HU - Ungheria 13
IL - Israele 13
GR - Grecia 12
NZ - Nuova Zelanda 11
AL - Albania 9
NO - Norvegia 9
RS - Serbia 9
BY - Bielorussia 8
DO - Repubblica Dominicana 8
JM - Giamaica 8
MD - Moldavia 8
NP - Nepal 8
BH - Bahrain 7
CR - Costa Rica 7
KG - Kirghizistan 7
OM - Oman 7
BO - Bolivia 6
ET - Etiopia 6
GE - Georgia 6
GT - Guatemala 6
HN - Honduras 6
LB - Libano 6
LI - Liechtenstein 6
TH - Thailandia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
AM - Armenia 5
LV - Lettonia 5
MO - Macao, regione amministrativa speciale della Cina 5
SK - Slovacchia (Repubblica Slovacca) 5
TZ - Tanzania 5
BA - Bosnia-Erzegovina 4
SN - Senegal 4
EE - Estonia 3
GA - Gabon 3
GD - Grenada 3
LA - Repubblica Popolare Democratica del Laos 3
Totale 69.029
Salva come PNG Salva come JPEG
Città #
Southend 3.800
Santa Clara 3.408
Fairfield 2.984
Ashburn 2.911
Singapore 2.597
Houston 2.374
Woodbridge 2.115
Chandler 2.090
Hefei 1.807
Hong Kong 1.673
Ann Arbor 1.257
Jacksonville 1.240
Frankfurt am Main 1.230
Seattle 1.166
Dearborn 1.142
Cambridge 1.113
Wilmington 1.070
Nyköping 1.012
Modena 824
London 770
Beijing 730
Los Angeles 557
New York 499
Seoul 451
Chicago 395
Ho Chi Minh City 289
Princeton 289
San Diego 271
Sofia 268
Shanghai 263
Moscow 258
Kraków 255
Council Bluffs 247
Munich 237
Helsinki 233
Eugene 229
The Dalles 222
Milan 209
Jakarta 204
Izmir 196
Bologna 176
Fremont 175
São Paulo 174
Buffalo 170
Hanoi 169
Boardman 159
Redwood City 154
Brussels 128
Des Moines 126
Dublin 126
Salt Lake City 126
Bremen 123
Warsaw 114
Rome 113
Tokyo 106
Dallas 97
Parma 94
Ottawa 89
Guangzhou 86
Denver 82
Phoenix 76
Columbus 74
Reggio Emilia 74
Tampa 73
Brooklyn 70
Falls Church 67
Elk Grove Village 66
Turku 66
Kent 65
Orem 65
San Jose 65
Atlanta 60
Grafing 58
Stockholm 58
Rio de Janeiro 54
Amsterdam 52
Chennai 52
Dong Ket 52
Milwaukee 52
Montreal 52
Toronto 51
Verona 51
Poplar 50
Johannesburg 49
Naples 49
Nanjing 47
Turin 47
Belo Horizonte 46
Norwalk 45
San Mateo 45
Jinan 42
Paris 42
Redondo Beach 42
Mexico City 41
Padova 41
Boston 40
Brasília 39
Nuremberg 39
Hangzhou 36
Kunming 36
Totale 47.601
Salva come PNG Salva come JPEG
Nome #
Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase 1.158
STRUTTURA DEL CRISTALLO DEL COMPLESSO DI TIMIDILATO SINTETASI (TS) CON UN LIGANDO 765
TYDOCK PHARMA s.r.l. Spin Off dell'Università di Modena e Reggio Emilia che ha come fine l'attività di ricerca e sviluppo nel settore delle biotech farmaceutiche. 578
Spermidine/spermine N1-acetyltranferasemodulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistanthuman ovarian cancer cell lines 417
Distamycin A and derivatives as synergic drugs in cisplatin-sensitive and -resistant ovarian cancer cells. 413
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells 411
Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase 408
An Improved Synthesis of CENTA, a Chromogenic Substrate for β-Lactamases 406
Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase 404
Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics 402
Metodo per la funzionalizzazione sito specifica di molecole proteiche 400
Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase 379
New thymidylate synthase inhibitors induce apoptosis in melanoma cell lines 378
USO DI INIBITORI DELLA PTERIDINA REDUTTASI PER LA PREVENZIONE E/O IL TRATTAMENTO DI INFEZIONI PARASSITARIE 375
Internalization and stability of a thymidylate synthase peptide inhibitor in ovarian cancer cells 372
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 369
Aryl thiosemicarbazones for the treatment of trypanosomatidic infections 362
Optimization of Peptides That Target Human Thymidylate Synthase to Inhibit Ovarian Cancer Cell Growth 360
Cyclic Peptides Acting as Allosteric Inhibitors of Human Thymidylate Synthase and Cancer Cell Growth 357
Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections 354
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines 352
Biochemistry: Anchors away 350
2-[N-Alkyl(R-phenyl)-aminomethyl]-3-phenyl-7-trifluoromethylquinoxalines as anticancer agents inhibitors of folate enzymes 348
Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones? 346
Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform 344
Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth 342
Improving specificity vs bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine 340
Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery 340
Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology 334
Repurposing of drugs targeting yap-tead functions 333
Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance 327
A condensed thiadiazolo-pyrimidine as a new efficient fluorophore. Theoretical and experimental investigation of the electronic spectra and photophysics 326
Decoding the structural basis for carbapenem hydrolysis by class A β- lactamases: fishing for a pharmacophore 324
Antibacterial agent discovery using thymidylate synthase biolibrary screening 323
Structure-based studies on species-specific inhibition of thymidylate synthase 320
Constrained dansyl derivatives reveal bacterial specificity of highly conserved Thymidylate Synthases A 320
Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides 320
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs 315
2′-Deoxyuridine 5′-Monophosphate Substrate Displacement in Thymidylate Synthase through 6-Hydroxy-2H-naphtho[1,8-bc]furan-2-one Derivatives 315
Proteomic and bioinformatic studies for the characterization of response to pemetrexed in platinum drug resistant ovarian cancer 315
Translational repression of thymidylate synthase by targeting its mRNA 313
The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment 309
Alanine Mutants of the Interface Residues of Human Thymidylate Synthase Decode Key Features of the Binding Mode of Allosteric Anticancer Peptides 307
Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-beta-lactamases 306
Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins 306
Dimer-monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer 305
NUOVE MOLECOLE, PER USO COME AGENTI ANTITUMORALI 304
pH-Promoted Release of a Novel Anti-Tumour Peptide by “Stealth” Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells 302
Crystal Structure of histidine-tagged human thymidylate synthase 300
Proteomic Approach to the Detection of the Mechanism of Action of Anticancer Peptides 298
Structure-Based Selectivity Optimization of Piperidine–Pteridine Derivatives as Potent Leishmania Pteridine Reductase Inhibitors 296
Current and Future Chemotherapy for Chagas Disease 296
Allosteric Inhibition of human Thymidylate Synthase. 296
The Inhibition of Extended Spectrum beta-Lactamases: Hits and Leads 294
ACS Medicinal Chemistry Letters. member of the Editorial Board 293
A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells 292
Thymidylate synthase inhibition: A structure-based rationale for drug design 290
Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents 287
Theoretical study of electronic spectra and photophysics of uracil derivatives. 287
Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections 286
Multiligand approach to the identification of resistant strains overexpressing beta-lactamase 284
ANTICANCER DRUGS 283
Conformational analysis of phthalein derivatives acting as thymidylate synthase inhibitors by means of 1H NMR and quantum chemical calculations 282
Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding 282
CYCLIZATION REACTIONS OF 1,3-DIBROMOPROPAN-2-OL, 2,3-DIBROMOPROPAN-1-OL AND 1-BROMOMETHYLOXIRANE WITH 6-AMINO-2,3-DIHYDRO-2-THIOXO-4(1H)-PYRIMIDINONE 281
Aprepitant as anticancer drug 281
A proteomic approach to investigate the mechanism of action of anticancer peptides 281
Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To InhibitTrypanosoma bruceiPteridine Reductase in Support of Early-Stage Drug Discovery 281
“A step further in the discovery of phthalein derivatives as Thymidylate Synthase inhibitors” 281
Crystal Structure of human thymidylate synthase bound to a peptide inhibitor 279
Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds 279
Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors 279
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity 279
Thymidylate synthase structure, function and implication in drug discovery 277
PTEROATE-PEPTIDE BIOCONJUGATE TARGETING THE FOLATE RECEPTOR IN HUMAN OVARIAN CANCER CELL LINES: TRANSPORT AND MECHANISM OF ACTION. 277
Maxwell A: F1000Prime Recommendation of Evaluation [Neres J et al., ACS Chem Biol 2014]. In F1000Prime, 09 Jan 2015; DOI: 10.3410/f.725248139.793502885. F1000Prime.com/725248139#eval793502885 276
Hotspots in an obligate homodimeric anticancer target. structural and functional effects of interfacial mutations in human thymidylate synthase 275
X-ray-crystallography deciphers the activity of broad spectrum boronic acid β-Lactamases inhibitors 275
Alternative strategies in medicinal chemistry to face drug resistance in anticancer therapy. 274
Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells 274
IN SILICO/IN VITRO APPROACHES FOR THE IDENTIFICATION OF NEW CARBAPENEMASE INHIBITORS 272
Homodimeric Enzymes as Drug Targets 269
Permeation through the cell membrane of a boron-based β-lactamase inhibitor. 269
Theoretical analysis of the addition of hydroxylamine to uracil and 5-fluorouracil as a model for the Thymidylate synthase reaction 265
1H-NMR conformational studies of some phtalein derivatives acting as thymidylate synthase inhibitors 265
Ligand-based discovery of N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide derivatives as thymidylate synthase A inhibitors 265
Development of flavonoids derivatives as leads against Leishmaniasis and Trypanosomiasis-invited lecture 265
Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting 265
Tethering low affinity ligands to the dimeric interface of human thymidylate synthase. 263
Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus 263
Protein-protein interaction inhibitors: case studies on Small Molecules and Natural Compounds. 262
Biochemical effects of riluzole on Leishmania parasites 262
Pirrole-amidine oligopeptide–DNA interaction studies through Isothermal Titration Calorimetry 258
SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent 258
Update on antifolate drugs targets 257
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity 257
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 255
Zing meeting on Medicinal Chemistry 2012-Lanzarote-invitated lecture 253
TSI INDUCES APOPTOSIS WITH A P53 INDIPENDENT PATHWAY IN MELANOMA CELL LINES AND IN NORMAL HUMAN MELANOCITES 253
Optimizing Cell Permeation of an Antibiotic Resistance Inhibitor for Improved Efficacy 252
Totale 32.477
Salva come PNG Salva come JPEG
Categoria #
all - tutte 260.444
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 260.444
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.487 0 0 0 0 0 621 558 770 381 1.171 571 415
2021/20225.532 246 536 330 303 243 554 249 356 626 393 1.058 638
2022/20236.329 759 759 421 608 644 897 190 604 753 103 308 283
2023/20245.689 202 278 326 412 1.996 486 280 492 138 133 387 559
2024/202514.297 602 197 432 947 2.670 1.880 988 807 1.437 649 1.712 1.976
2025/202613.157 1.699 1.183 2.043 2.935 3.804 1.493 0 0 0 0 0 0
Totale 69.804